Unknown

Dataset Information

0

Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.


ABSTRACT: Antibodies, and engineered antibody fragments, labeled with radioisotopes are being developed as radiotracers for the detection and phenotyping of diseases such as cancer. The development of antibody-based radiotracers requires extensive characterization of their in vitro and in vivo properties, including their ability to target tumors in an antigen-selective manner. In this study, we investigated the use of Cerenkov luminescence imaging (CLI) as compared with PET as a modality for evaluating the in vivo behavior of antibody-based radiotracers.The anti-prostate-specific membrane antigen (PSMA) huJ591 antibody (IgG; 150 kDa) and its minibody (Mb; 80 kDa) format were functionalized with the chelator 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) and radiolabeled with the positron-emitting radionuclide 64Cu (half-life, 12.7 h). Immunoreactive preparations of the radiolabeled antibodies were injected into NCr nu/nu mice harboring PSMA-positive CWR22Rv1 and PSMA-negative PC-3 tumor xenografts. Tumor targeting was evaluated by both PET and CLI.64Cu-NODAGA-PSMA-IgG and 64Cu-NODAGA-PSMA-Mb retained the ability to bind cell surface PSMA, and both radiotracers exhibited selective uptake into PSMA-positive tumors. Under the experimental conditions used, PSMA-selective uptake of 64Cu-NODAGA-PSMA-IgG and 64Cu-NODAGA-PSMA-Mb was observed by CLI as early as 3 h after injection, with tumor-to-background ratios peaking at 24 (IgG) and 16 (Mb) h after injection. Targeting data generated by CLI correlated with that generated by PET and necropsy.CLI provided a rapid and simple assessment of the targeting specificity and pharmacokinetics of the antibody-based PET radiotracers that correlated well with the behavior observed by standard PET imaging. Moreover, CLI provided clear discrimination between uptake kinetics of an intact IgG and its small-molecular-weight derivative Mb. These data support the use of CLI for the evaluation of radiotracer performance.

SUBMITTER: D'Souza JW 

PROVIDER: S-EPMC5209641 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.

D'Souza Jimson W JW   Hensley Harvey H   Doss Mohan M   Beigarten Charles C   Torgov Michael M   Olafsen Tove T   Yu Jian Q JQ   Robinson Matthew K MK  

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20160818 1


Antibodies, and engineered antibody fragments, labeled with radioisotopes are being developed as radiotracers for the detection and phenotyping of diseases such as cancer. The development of antibody-based radiotracers requires extensive characterization of their in vitro and in vivo properties, including their ability to target tumors in an antigen-selective manner. In this study, we investigated the use of Cerenkov luminescence imaging (CLI) as compared with PET as a modality for evaluating th  ...[more]

Similar Datasets

| S-EPMC3083828 | biostudies-literature
| S-EPMC3068779 | biostudies-literature
| S-EPMC4167912 | biostudies-literature
| S-EPMC3903390 | biostudies-literature
| S-EPMC5037157 | biostudies-literature
| S-EPMC3812546 | biostudies-literature
| S-EPMC5558792 | biostudies-other
| S-EPMC4887274 | biostudies-literature
| S-EPMC3891931 | biostudies-literature